Illumina (NASDAQ:ILMN) updated its FY20 earnings guidance on Wednesday. The company provided EPS guidance of $6.80-7.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.98. The company issued revenue guidance of $3.86-3.93 billion, compared to the consensus revenue estimate of $3.92 billion.Illumina also updated its FY 2020
After-Hours guidance to 6.80-7.00 EPS.
A number of research analysts have recently commented on the stock. Citigroup assumed coverage on shares of Illumina in a report on Monday, January 6th. They issued a buy rating and a $385.00 price target on the stock. Cowen restated an outperform rating and issued a $335.00 price target (up from $320.00) on shares of Illumina in a report on Wednesday, December 18th. Wells Fargo & Co assumed coverage on shares of Illumina in a report on Tuesday, January 7th. They issued an underweight rating and a $300.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Illumina in a report on Thursday, November 14th. They issued a buy rating and a $345.00 price target on the stock. Finally, Piper Jaffray Companies cut their price target on shares of Illumina from $348.00 to $341.00 and set an overweight rating on the stock in a report on Friday, October 25th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $339.81.
Shares of NASDAQ:ILMN traded down $0.98 during trading on Wednesday, reaching $313.30. The stock had a trading volume of 1,243,465 shares, compared to its average volume of 1,108,730. Illumina has a one year low of $263.30 and a one year high of $380.76. The company has a market capitalization of $46.98 billion, a P/E ratio of 47.83, a PEG ratio of 2.20 and a beta of 1.05. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41. The firm’s 50-day simple moving average is $326.58 and its 200 day simple moving average is $306.32.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.12. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The business had revenue of $953.00 million for the quarter, compared to analysts’ expectations of $950.16 million. During the same period last year, the business earned $1.32 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. Equities research analysts forecast that Illumina will post 6.46 earnings per share for the current fiscal year.
In related news, SVP Charles Dadswell sold 193 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $297.28, for a total value of $57,375.04. Following the completion of the transaction, the senior vice president now directly owns 5,069 shares of the company’s stock, valued at approximately $1,506,912.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sam Samad sold 892 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $320.00, for a total transaction of $285,440.00. Following the completion of the transaction, the chief financial officer now directly owns 3,461 shares of the company’s stock, valued at $1,107,520. The disclosure for this sale can be found here. Insiders sold a total of 3,920 shares of company stock valued at $1,262,212 over the last ninety days. 0.38% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: How does a security become overbought?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
